Marco Pravetoni, PhD
The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.
Education
PhD in Pharmacology, University of Minnesota, 2008
Department Affiliations
Scholarly Expertise
- Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling
Recent Publications
(2025 Oct 11)
Biomaterials 327(): 123776
Bian Y, Ci Q, Rostamizadeh K, Marecki C, Hamid FA, DeHority R, Qian Z, Walter DL, Pravetoni M, Zhang C
(2025 Oct 6)
J Control Release 388(Pt 1): 114294
Hamid FA, Rostamizadeh K, Skiados N, Le NN, Walter DL, Hannon B, Marecki C, Bian Y, Luengas D, Zhang C, Pravetoni M
(2025 Aug 30)
Vaccine 62(): 127488
Tronconi D, Marecki C, Seaman RW Jr, Hannon B, Kim CM, Hamid FA, Pravetoni M
(2025 Sep)
Drug Alcohol Depend Rep 16(): 100365
Galbo-Thomma LK, Baehr C, Gay EA, Runyon S, Pravetoni M, France CP
(2025 Sep-Oct)
Int J Toxicol 44(5): 395-406
Walter D, Ci Q, Hu H, DeHority R, Hinckley J, Bian Y, Serpa PBS, Southard T, Werre SR, Pravetoni M, Ehrich M, Zhang C
Show complete publication list »
